LOTRIDERM CREAM

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE); CLOTRIMAZOLE

Доступна з:

ORGANON CANADA INC.

Код атс:

D01AC20

ІПН (Міжнародна Ім'я):

IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS

Дозування:

0.05%; 1%

Фармацевтична форма:

CREAM

Склад:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%; CLOTRIMAZOLE 1%

Адміністрація маршрут:

TOPICAL

Одиниць в упаковці:

15G/50G

Тип рецепту:

Prescription

Терапевтична области:

ANTI-INFLAMMATORY AGENTS

Огляд продуктів:

Active ingredient group (AIG) number: 0216399001; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2011-02-15

Характеристики продукта

_LOTRIDERM_
_®_
_ Cream (Clotrimazole and Betamethasone Dipropionate Cream, Organon
Standard) _
_ _
_Page 1 of 17_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
LOTRIDERM
®
Clotrimazole and Betamethasone Dipropionate Cream, Organon Standard
Topical Antifungal and Corticosteroid Agent
ORGANON CANADA INC.
16766 route Transcanadienne
Kirkland, Quebec
H9H 4M7
www.organon.ca
Date of Initial Approval:
December 31, 1990
Date of Revision:
April 20, 2021
Submission Control No.: 250115
_ _
_LOTRIDERM_
_®_
_ Cream (Clotrimazole and Betamethasone Dipropionate Cream, Organon
Standard) _
_ _
_Page 2 of 17_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
1
INDICATIONS
..................................................................................................................3
1.1
Pediatrics
....................................................................................................................3
1.2
Geriatrics
....................................................................................................................3
2
CONTRAINDICATIONS
.................................................................................................3
3
DOSAGE AND ADMINISTRATION
.............................................................................3
3.1
Dosing Considerations
...............................................................................................3
3.2
Recommended Dose and Dosage Adjustment
...........................................................3
3.3
Administration
...........................................................................................................4
4
MISSED DOSE
..................................................................................................................4
5
OVERDOSAGE
.................................................................................................................4
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................5
7
WARNIN